E
Epic bio
Biotech & Life Sciences · South San Francisco, United States · Founded 2018
Relentless focus on ushering in a new era of gene regulation MoreLess
Epic Bio is a pioneering startup operating in the field of genetic medicine, with a focus on developing innovative therapies to control gene expression and treat complex diseases. The company leverages the power of epigenetics, a system present in all mammalian cells that controls gene expression, to create new therapeutic possibilities.
The company's primary offering is its Gene Expression Modulation System (GEMS), a platform that allows for the creation of customized therapies for specific disease indications. This "mix and match" platform uses a toolbox of epigenomic modulators, providing vast possibilities for disease treatment.
Epic Bio operates in the biotechnology market, serving clients in the healthcare sector, including hospitals, clinics, and other medical institutions. The company's business model revolves around the development and sale of its GEMS platform and the therapies it can create. Revenue is generated through the sale of these therapies to healthcare providers and institutions.
The company also prides itself on being a place where individuals can advance their careers, do groundbreaking work, and make a real impact on the world. This is evidenced by their recognition in the 2023 Endpoints 20 Under 40 and the 2022 Endpoints Women in R&D.
Keywords: Genetic Medicine, Epigenetics, Gene Expression, Therapies, Disease Treatment, Biotechnology, Healthcare, GEMS Platform, Career Advancement, Recognition.
Company overview
Epic bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 44
- Open positions
- 7
- Dealroom signal
- 82.2
Valuation & funding
Epic bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2025 | $68M | $272M | SOLVE FSHD · Ally Bridge Group | ↗ |
| GRANTOther financing | Apr 2023 | $0 | — | SOLVE FSHD | ↗ |
| SERIES AOther financing | Jul 2022 | $55M | $220M | Undisclosed | ↗ |
| SPINOUTOther financing | Jan 2018 | $0 | — | Stanford University | — |
Growth signals
Epic bio website traffic
Latest recorded traffic for Epic bio is 5.6K monthly website visits, up 115.4% over the last three months. Epic bio's team declined 2.2% over the past year.
Hiring
Open positions at Epic bio
Current openings linked to this company in Dealroom.
Comparisons
Epic bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Epic bio's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Epic bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Epic bio has talent and traffic
team presence
In the news
Latest news about Epic bio
Recent press, funding announcements, and product moves mentioning Epic bio — open to read from the original sources.
Market sentiment
What the market is saying about Epic bio
An AI-synthesized read of the highest-engagement posts about Epic bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epic bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.